Real-World Experience of Tixagevimab and Cilgavimab (Evusheld) in Rheumatologic Patients on Rituximab
Authors:
- 20 September 2022
- journal article
- research article
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 29 (2) , 109-111
Abstract
Background/Objective: Although vaccination is the primary strategy against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), rheumatologic patients on B-cell depleting agent rituximab may have a suboptimal response. Tixagevimab and cilgavimab (Evusheld) could be administered under Food and Drug Administration emergency use authorization as pre-exposure prophylaxis. Methods: A cohort study of rheumatologic patients on rituximab therapy who received Evusheld was followed longitudinally. Adverse events were monitored. Results: Forty-three patients received Evusheld, with diagnoses including rheumatoid arthritis, ANCA vasculitis, immune-mediated myositis, Sjögren disease, and systemic lupus erythematosus. Average time to follow-up was 100 ± 33 days. One patient experienced symptomatic infection with SARS-CoV-2 confirmed by home antigen test twice. A total of 97.8% of patients during follow-up did not contract acute SARS-CoV-2 infection. At the same time, 32,074 new local cases were reported with a local cumulative SARS-CoV-2 incidence rate of 4.32%. Adverse events included myalgia, flu-like symptoms, fevers, injection site pain, or headache. No serious adverse events, anaphylaxis, or cardiac events occurred. Conclusions: Evusheld demonstrated effectiveness in preventing symptomatic SARS-CoV-2 infection in a real-world cohort of rheumatologic patients on rituximab therapy. Administration of Evusheld may be considered as part of a multilayered approach to risk mitigation in this high-risk population as pre-exposure prophylaxis.Keywords
This publication has 8 references indexed in Scilit:
- Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With RituximabJAMA Network Open, 2022
- Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19New England Journal of Medicine, 2022
- The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humansScience Translational Medicine, 2022
- Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19JAMA, 2022
- Immunogenicity of SARS-CoV-2 vaccination in rituximab-treated patients: Effect of timing and immunologic parametersClinical Immunology, 2021
- BNT162b2 COVID‐19 vaccine is significantly less effective in patients with hematologic malignanciesAmerican Journal of Hematology, 2021
- Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking EraOpen Forum Infectious Diseases, 2021
- COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort studyThe Lancet Rheumatology, 2021